Apogee Therapeutics, Inc. Common Stock (APGE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apogee Therapeutics, Inc. Common Stock (APGE) has a cash flow conversion efficiency ratio of -0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.38 Million) by net assets ($1.19 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Apogee Therapeutics, Inc. Common Stock for the company's overall valuation and market capitalisation.
Apogee Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Apogee Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apogee Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apogee Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See Apogee Therapeutics, Inc. Common Stock debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vietnam Prosperity Joint Stock Commercial Bank
VN:VPB
|
0.065x |
|
Redeia Corporacion S.A.
MC:RED
|
0.064x |
|
Blueprint Medicines Corp
NASDAQ:BPMC
|
-0.159x |
|
Jiangsu Yanghe Brewery Joint-Stock Co Ltd
SHE:002304
|
0.010x |
|
AU Small Finance Bank Limited
NSE:AUBANK
|
-0.363x |
|
Lincoln National Corporation
NYSE:LNC
|
-0.049x |
|
SPIE SA
PA:SPIE
|
0.362x |
|
SAINSBURY -J.- ADR/4 NEW
F:SUY
|
N/A |
Annual Cash Flow Conversion Efficiency for Apogee Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Apogee Therapeutics, Inc. Common Stock from 2022 to 2025. View APGE live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $903.88 Million | $-227.45 Million | -0.252x | -5.37% |
| 2024-12-31 | $716.79 Million | $-171.17 Million | -0.239x | -21.35% |
| 2023-12-31 | $379.91 Million | $-74.76 Million | -0.197x | -70.20% |
| 2022-12-31 | $142.07 Million | $-16.43 Million | -0.116x | -- |
About Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more